TABLE 3.

Descriptive characteristics of FAERS reports for lecanemab and donanemab.

Description	Lecanemab	Donanemab	Overall
Number of reports	(N = 2,602)	(N = 1,038)	(N = 3,640)
Sex
Female	1,397 (53.7%)	492 (47.4%)	1889 (51.9%)
Male	962 (37.0%)	290 (27.9%)	1,252 (34.4%)
Missing	243 (9.3%)	256 (24.7%)	499 (13.7%)
Age (years)
<18	2 (0.1%)	1 (0.1%)	3 (0.1%)
18–64	211 (8.1%)	27 (2.6%)	238 (6.5%)
65–85	1,681 (64.6%)	425 (40.9%)	2,106 (57.9%)
>85	60 (2.3%)	20 (1.9%)	80 (2.2%)
Missing	648 (24.9%)	565 (54.4%)	1,213 (33.3%)
Report types
Consumer	683 (26.2%)	943 (90.8%)	1,626 (44.7%)
Health professional	371 (14.3%)	52 (5.0%)	423 (11.6%)
Pharmacist	49 (1.9%)	7 (0.7%)	56 (1.5%)
Physician	1,049 (40.3%)	16 (1.5%)	1,065 (29.3%)
Missing	450 (17.3%)	20 (1.9%)	470 (12.9%)
Report countries
United States	2,189 (84.1%)	973 (93.7%)	3,162 (86.9%)
Japan	328 (12.6%)	2 (0.2%)	330 (9.1%)
China	33 (1.3%)	16 (1.5%)	49 (1.3%)
South Korea	22 (0.8%)	0 (0.0%)	22 (0.6%)
United Kingdom	4 (0.2%)	2 (0.2%)	6 (0.2%)
Report years
2023	242 (9.3%)	0 (0.0%)	242 (6.6%)
2024	1,249 (48.0%)	70 (6.7%)	1,319 (36.2%)
2025	1,111 (42.7%)	968 (93.3%)	2079 (57.1%)